Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.
Contemporary Clinical Trials March 2, 2026 Samuel T. Wilkinson, Sandhya Prashad, Rachel Dalthorp et al. 1 citation
Ketamine is a powerful and rapid-acting antidepressant but has no regulatory authorization for any psychiatric illness. The S-enantiomer of ketamine, esketamine, was approved by the FDA in 2019 as adjunctive therapy for treatment-resistant depression. Substantial controversy exists as to whether there is a significant clinical difference between intravenous (IV) ketamine racemate and intranasal...
DOI: 10.1016/j.cct.2026.108273 (opens in new tab)
Ketamine
Humans
Antidepressive agents
Administration, intranasal
+6